Past Issue

Volume 20, Number 1, Spring 2018, Serial Number: 77 Pages: 113-119

Semaphorin-3A as An Immune Modulator Is Suppressed by MicroRNA-145-5p


Mahsa Rezaeepoor, M.Sc, 1, Mazdak Ganjalikhani-hakemi, Ph.D, 1, *, Shima Shapoori, M.Sc, 1, Nahid Eskandari, Ph.D., 1, Mohammadreza Sharifi, Ph.D., 2, Masoud Etemadifar, M.D., 3, Mansuorian Marjan, Ph.D., 4,
Department of Immunology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
Department of Genetics, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
Multiple Sclerosis and Neuroimmunology Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
Department of Biostatistics and Epidemiology, Faculty of Medicine, Isfahan University of Medical Science, Isfahan, Iran
*Corresponding Address: P.O. BOX: 8174673461 Department of Immunology Faculty of Medicine Isfahan University of Medical Sciences Isfahan Iran Email:mghakemi@med.mui.ac.ir

Abstract

Objective

Semaphorin-3A (SEMA3A) and its receptors are found on some immune cells and act as suppressors of immune cells over-activation. Considering the role of SEMA3A and its down-regulation in some autoimmune diseases, as well as our bioinformatics predictions, we assumed that miR-145-5p might affect SEMA3A expression. So, we aimed to determine the effect of miR-145-5p on SEMA3A gene expression level.

Materials and Methods

In this experimental study, we evaluated the effect of miR-145-5p transfection on SEMA3A expression in peripheral blood mononuclear cells (PBMCs) using ELISA and quantitative real-time polymerase chain reaction (PCR) methods.

Results

Our results showed that miR-145-5p is able to decrease SEMA3A expression at both protein and mRNA levels. These data confirmed our previous bioinformatic prediction about the inhibitory effect of miR-145-5p on SEMA3A expression.

Conclusion

These results enlightened us about an unknown aspect of SEMA3A role in some autoimmune disorders like multiple sclerosis (MS) and rheumatoid arthritis (RA) and also proposed SEMA3A as a potential therapeutic approach.